A New Chapter in Cardiometabolic Research Novo Nordisk has announced plans to present significant new clinical data regarding Wegovy (semaglutide) at the upcoming American Diabetes Association (ADA) 2026 Scientific Sessions. The upcoming presentation aims to broaden the clinical understanding of the drug’s impact beyond its primary use cases. What to Expect at the 2026 Scientific…